Atlas Trials

Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

Clinical trial NCT06052800 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06052800
Sponsor
Sanofi
Status
ACTIVE_NOT_RECRUITING
Study type
OBSERVATIONAL
Fabry Disease
Start date
2023-09-13
Primary completion
2026-09-10
Enrollment
78

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.